1. A strategy of targeting B10 cell by CD19scFv-IL10R for tumor therapy
- Author
-
Qin Pan, Chun Huang, Min Liu, Rong Zhao, Xiao-Lian Zhang, Xin Li, Jia-Hui Deng, and Han-Yu Chen
- Subjects
Cytotoxicity, Immunologic ,Serum ,0301 basic medicine ,Recombinant Fusion Proteins ,Antigens, CD19 ,Cell ,Biophysics ,chemical and pharmacologic phenomena ,Biochemistry ,CD19 ,03 medical and health sciences ,Plasmid ,Cell Line, Tumor ,Neoplasms ,medicine ,Animals ,Cytotoxic T cell ,Receptors, Interleukin-10 ,Molecular Biology ,B-Lymphocytes, Regulatory ,biology ,Chemistry ,Immunity ,T-Lymphocytes, Helper-Inducer ,Cell Biology ,Transfection ,Fusion protein ,Mice, Inbred C57BL ,Interleukin 10 ,030104 developmental biology ,medicine.anatomical_structure ,Cancer research ,biology.protein ,CD8 ,Plasmids ,Protein Binding ,Single-Chain Antibodies - Abstract
IL-10 producing B (B10) cells, a subset of regulatory B (Breg) cells, produce IL-10 and play immunosuppressive roles in antitumor immunity. B10 cells are associated with enhanced tumor-aggressiveness and a poorer prognosis. To specifically inhibit the IL-10 secreted by B cells, we constructed the recombinant plasmid pcCD19scFv-IL10R, which contained the gene of anti-CD19 single-chain variable fragment (CD19scFv) and the extracellular domain of IL-10R1. Soluble CD19scFv-IL10R protein was identified in vitro and in vivo after the cells were transfected with pcCD19scFv-IL10R plasmid or the mice were injected with the plasmid. The fusion protein had the bispecific ability to target both IL-10 and CD19 molecules in vitro. Intramuscularly (i.m.) injecting mice with pcCD19scFv-IL-10R plasmid inhibited hepatocellular carcinoma growth in vivo. Mice treated with pcCD19scFv-IL-10R showed a significant reduction in B10 cells and regulatory T (Treg) cells, but an increase in the anti-tumor Th1 immune response and the cytotoxic CD8+ T cell response. Thus, targeting B10 cells by CD19scFv-IL10R molecule may offer a new avenue for tumor therapy.
- Published
- 2018
- Full Text
- View/download PDF